NCT00825019已完成3 期
A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 306
- 试验地点
- 1
- 主要终点
- change from baseline of the total score of the HAM-D 17 items
研究概览
简要总结
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive episode (MDD).
Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients suffering from a recurrent major depressive episode of at least moderate intensity (DSM-IV)
- •patients have been hospitalized for the treatment of a previous episode, or a previous episode required antidepressant treatment(s)at the recommended dose level for at least 2 months.
- •the duration of the current episode is of at least six weeks unless the severity of symptoms justifies shorter duration.
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: amibegron (SR58611A) (Drug)
2
Placebo Comparator
干预措施: placebo (Drug)
3
Active Comparator
paroxetine
干预措施: paroxetine (Drug)
结局指标
主要结局
change from baseline of the total score of the HAM-D 17 items
时间窗: 6 weeks
次要结局
- HAM-D subscores, HAMD responders and remitters, HAM-A total score and subscores(6 weeks)
- Montgomery-Asberg Depression Rating Scale (MADRS) total score(6 weeks)
- clinical global impression (CGI) severity and improvement scores(6 weeks)
- patient global impression (PGI) improvement score(6 weeks)
- social and occupational functioning assessment scale (SOFAS) score(6 weeks)
- AEs, Arizona Sexual Experience Scale (ASEX),(6 weeks)
- laboratory parameters, physical examination findings, ECG parameters, change of vital signs, body weight(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of SR58611 Compared to Placebo and ParoxetineMajor Depressive DisordersNCT00825058Sanofi317
已完成
2 期
Dose-finding Study With Lu AA24530 in Major Depressive DisorderMajor Depressive DisorderNCT00599911H. Lundbeck A/S652
已完成
3 期
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive DisorderMajor Depressive DisorderNCT00863798Wyeth is now a wholly owned subsidiary of Pfizer682
已完成
3 期
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive DisorderMajor Depressive DisorderNCT00798707Pfizer709
Unknown
4 期
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of SchizophreniaSchizophreniaNCT01300364Fundació Sant Joan de Déu249